This product page provides a laboratory-focused overview of three research-use compounds frequently evaluated in preclinical studies of nicotinamide metabolism and methylation-dependent metabolic regulation: Nicotinamide Mononucleotide (NMN), 5-Amino-1MQ (a small-molecule NNMT inhibitor class representative), and JBSNF-000088 (6-methoxynicotinamide).

In experimental systems, these compounds are used as biochemical tools to investigate NAD salvage dynamics, nicotinamide N-methyltransferase (NNMT) enzymatic activity, methyl-donor utilization, and downstream molecular readouts related to energy substrate handling, transcriptional regulation, and metabolite partitioning. All discussions herein are restricted to in-vitro, ex-vivo, or in-vivo animal research contexts.

Nicotinamide Mononucleotide (NMN): NMN is a phosphorylated nicotinamide riboside intermediate within the NAD salvage pathway. In laboratory research, NMN is utilized to modulate intracellular NAD pools and to examine downstream effects on NAD-dependent enzymes such as sirtuins and poly(ADP-ribose) polymerases (PARPs).

5-Amino-1MQ: 5-Amino-1MQ is a membrane-permeable small-molecule compound reported in preclinical literature to inhibit NNMT enzymatic activity. NNMT catalyzes the methylation of nicotinamide using S-adenosyl-L-methionine (SAM), yielding 1-methylnicotinamide (MNA) and S-adenosyl-L-homocysteine (SAH).

JBSNF-000088 (6-Methoxynicotinamide): JBSNF-000088 is a nicotinamide analog studied in animal models for its influence on NNMT-associated metabolite profiles. Preclinical investigations often assess tissue-specific concentrations of MNA and related metabolites following exposure.

• Investigation of NAD salvage pathway flux and NAD-dependent enzyme activity
• NNMT inhibition studies including enzyme kinetics and target engagement assays
• Analysis of methyl-donor utilization (SAM/SAH ratios) and one-carbon metabolism
• Quantification of glucose transporter expression (e.g., GLUT4) in cellular and animal models
• Tissue-specific metabolomics profiling of nicotinamide-derived metabolites

NNMT occupies a regulatory position linking nicotinamide clearance with methyl-donor metabolism. By consuming SAM during nicotinamide methylation, NNMT activity influences intracellular methylation capacity, which is routinely evaluated in preclinical systems through metabolite ratios and transcriptional profiling.

NMN supplementation in experimental models is used to elevate NAD availability, thereby enabling mechanistic interrogation of NAD-dependent signaling pathways. These include redox reactions, post-translational protein modification, and DNA damage response signaling cascades.

Source: NCBI

Preclinical animal studies examining NNMT inhibition frequently report changes in adipose tissue morphology, metabolite distribution, and glucose handling metrics under controlled dietary conditions. These outcomes are evaluated using biochemical assays, histological analysis, and targeted gene expression profiling.

NMN-based studies in rodent models often quantify NAD pool size, mitochondrial enzyme activity, and transcriptional markers associated with metabolic adaptation. These measurements are used to map pathway-level responses to altered NAD availability.

Cellular Turnover and Genome Maintenance (Preclinical Context)

Some experimental systems additionally assess cellular turnover, progenitor cell abundance, and DNA damage response signaling. These analyses focus on measurable endpoints such as cell cycle markers, lineage-specific transcription factors, and DNA repair pathway activation states, without reference to organism-level functional outcomes.

Source: ResearchGate

Research-grade materials are typically characterized using analytical techniques including HPLC or UPLC for purity assessment, LC-MS for molecular weight confirmation, and NMR spectroscopy for structural verification. Certificates of Analysis (COA) may document purity, identity, and residual solvent content.

The above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Barbara B. Kahn is chief of the Division of Endocrinology, Diabetes, and Metabolism at Beth Israel Deaconess Medical Center (BIDMC) and the George Richards Minot Professor of Medicine at Harvard Medical School. She is an internationally recognized scientist in the area of obesity and type 2 diabetes, and her lab investigates the molecular mechanisms underlying these conditions, including the regulation of insulin action, food intake, and energy balance. Kahn received BA and MD degrees from Stanford University and an MS from the University of California at Berkeley. After completing internal medicine training at the UC Davis Medical Center, she began her career in molecular research at the National Institutes of Health. Kahn has received numerous awards including the Outstanding Scientific Achievement Award from the American Diabetes Association; the H. C. Jacobaeus Prize from the Novo Nordisk Foundation and the Karolinska Institutet; the Charles H. Best Lectureship and Award from the University of Toronto; and the Gerald D. Aurbach Award Lecture from the Endocrine Society. Kahn was elected to the Institute of Medicine of the National Academies and is a fellow of the American Association for the Advancement of Science.

Barbara B. Kahn is being referenced as one of the leading scientists involved in the research and development of NMN, 5-Amino-1MQ, and JBSNF-000088. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Barbara B. Kahn is listed in [1] under the referenced citations.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.

RUO Disclaimer